Achieve Life Sciences, Inc. (ACHV)
NASDAQ: ACHV · Real-Time Price · USD
4.270
+0.310 (7.83%)
At close: Apr 28, 2026, 4:00 PM EDT
4.130
-0.140 (-3.28%)
After-hours: Apr 28, 2026, 6:19 PM EDT
Achieve Life Sciences Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Achieve Life Sciences stock have an average target of 14.67, with a low estimate of 12 and a high estimate of 19. The average target predicts an increase of 243.56% from the current stock price of 4.27.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Achieve Life Sciences stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $13 | Strong Buy | Initiates | $13 | +204.45% | Apr 21, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +181.03% | Apr 16, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +181.03% | Mar 25, 2026 |
| Citizens | Citizens | Buy Initiates $19 | Buy | Initiates | $19 | +344.96% | Nov 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $12 | Strong Buy | Initiates | $12 | +181.03% | Aug 21, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
45.15M
EPS This Year
-1.40
from -1.25
EPS Next Year
-1.00
from -1.40
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 125.1M | ||||||
| Avg | n/a | 45.1M | ||||||
| Low | n/a | 20.3M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.20 | -0.23 | ||||||
| Avg | -1.40 | -1.00 | ||||||
| Low | -1.77 | -1.62 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.